SCHEMBL1334294

SCHEMBL1334294

N#Cc1cc(Oc2ccc(Oc3ccccc3)cc2)ccc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
MAOB P27338 2/20 0.48
MAOA P21397 1/20 0.48
CYP19A1 P11511 2/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPT P10636 3/20 0.47
GAA P10253 3/20 0.47
TSHR P16473 2/20 0.47
ALOX15 P16050 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MITF O75030 1/20 0.46
GFER P55789 1/20 0.46
NLRP1 Q9C000 1/20 0.46
NOD2 Q9HC29 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1335043 1.00 ALDH1A1 (0.49) ALDH1A1HPGDMAOBMAOACYP19A1
SCHEMBL11481973 0.93 NR4A1 (0.52) ALDH1A1HPGDCYP19A1MEN1KMT2A
SCHEMBL5073657 0.91 NR4A1 (0.54) ALDH1A1HPGDCYP19A1MEN1KMT2A
SCHEMBL28288026 0.86 GAA (0.53) ALDH1A1HPGDMAOBMAOACYP19A1
SCHEMBL1336627 0.85 MAOB (0.62) MAOBMAOAMAPTGAALMNA
SCHEMBL1336515 0.85 MAOB (0.58) MAOBMAOALTA4H
SCHEMBL8388704 0.84 AR (0.56) ALDH1A1HPGDMAOBMAOACYP19A1
SCHEMBL1333336 0.83 CYP19A1 (0.43) ALDH1A1HPGDCYP19A1MEN1KMT2A
SCHEMBL523446 0.83 ALDH1A1 (0.65) ALDH1A1HPGDMAOBMAOACYP19A1
SCHEMBL9747026 0.83 ALDH1A1 (0.65) ALDH1A1HPGDMAOBMAOACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP disclosed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US disclosed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US disclosed
EP-2373626-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010069966-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 ALDH1A1 1805/4885HPGD 2312/4885MAOB 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.